Key Highlights

  • Australian Clinical Labs (ASX:ACL) traded at A$3.24 during the 6 November 2026 session, up 1.25%.
  • FY26 total Revenue was A$735.8 million, down 0.7%.
  • Underlying EBITDA was A$204.5 million, up 0.2%, and underlying NPAT was A$35.5 million, up 4.3%.

Australian Clinical Labs (ASX:ACL) shares were quoted at A$3.24 during the 6 November 2026 trading session, up 1.25%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the FY26 results released on 17 August 2026. Australian Clinical Labs is an ASX-listed provider of pathology testing services in Australia.

Latest Developments

FY26 Financial Results (released 17 August 2026)

Total revenue from ordinary activities was A$735.8 million, down A$5.5 million or 0.7% on FY25. Underlying EBITDA was A$204.5 million, up 0.2%, and underlying NPAT was A$35.5 million, up 4.3%. The company's full annual financial report and investor presentation accompanied the results.

About the Company

Australian Clinical Labs is an ASX-listed pathology company headquartered in Clayton, Victoria, operating laboratories across Australia.

Business Overview

The company earns revenue from pathology testing, which depends on test volumes, referral patterns and government funding for pathology services.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Pathology providers are sensitive to Medicare funding, test volumes and labour costs.

Risks to Watch

Revenue fell slightly in FY26, and pathology funding settings can change. Labour and operating costs affect margins.

Catalysts on Watch

Investors may follow the H1 FY27 result, further progress on margins and any change in pathology funding.

Final Takeaways

Australian Clinical Labs (ASX:ACL) traded higher on 6 November 2026 in a session where the health care index eased. Its FY26 results, released on 17 August 2026, showed slightly lower revenue but higher underlying earnings.